Applied immunohistochemistry & molecular morphology · 2022 · 10 citations · 14 references
ComputingComputer ScienceOncologyComputer VisionMachine LearningMolecular OncologyComputational OncologyDeep LearningHer2-positive Breast CancerImmunohistochemistryRepresentation LearningTransfer LearningConvolutional Neural NetworksCross-validationDeep Learning-based DiagnosisExternal Validation CohortsHer2 AmplificationHer2 ExpressionHer2 Gene AmplificationInvasive Carcinoma Assessment
Invasive breast carcinomas are routinely tested for HER2 using immunohistochemistry (IHC), with reflex in situ hybridization (ISH) for those scored as equivocal (2+). ISH testing is expensive, time-consuming, and not universally available. In this study, we trained a deep learning algorithm to directly predict HER2 gene amplification status from HER2 2+ IHC slides. Data included 115 consecutive cases of invasive breast carcinoma scored as 2+ by IHC that had follow-up HER2 ISH testing. An external validation data set was created from 36 HER2 IHC slides prepared at an outside institution. All internal IHC slides were digitized and divided into training (80%), and test (20%) sets with 5-fold cross-validation. Small patches (256×256 pixels) were randomly extracted and used to train convolutional neural networks with EfficientNet B0 architecture using a transfer learning approach. Predictions for slides in the test set were made on individual patches, and these predictions were aggregated to generate an overall prediction for each slide. This resulted in a receiver operating characteristic area under the curve of 0.83 with an overall accuracy of 79% (sensitivity=0.70, specificity=0.82). Analysis of external validation slides resulted in a receiver operating characteristic area under the curve of 0.79 with an overall accuracy of 81% (sensitivity=0.50, specificity=0.82). Although the sensitivity and specificity are not high enough to negate the need for reflexive ISH testing entirely, this approach may be useful for triaging cases more likely to be HER2 positive and initiating treatment planning in centers where HER2 ISH testing is not readily available.
14
A survey on Image Data Augmentation for Deep Learning
Connor Shorten, Taghi M. Khoshgoftaar · Journal Of Big Data · 2019 · 12.4K citations · Full text
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Archives of Pathology & Laboratory Medicine · 2018 · 1.5K citations · Full text